biote (BTMD) Expected to Announce Earnings on Wednesday

biote (NASDAQ:BTMD) is projected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect biote to post earnings of $0.03 per share and revenue of $46.1240 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

biote (NASDAQ:BTMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $44.94 million for the quarter, compared to analyst estimates of $46.02 million. biote had a negative return on equity of 25.72% and a net margin of 8.29%. On average, analysts expect biote to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

biote Stock Performance

NASDAQ BTMD opened at $2.25 on Monday. The stock has a 50-day simple moving average of $2.20 and a 200 day simple moving average of $2.05. The company has a market capitalization of $84.56 million, a PE ratio of 5.11 and a beta of 1.64. biote has a 12 month low of $1.27 and a 12 month high of $4.55.

Institutional Trading of biote

Hedge funds have recently added to or reduced their stakes in the business. First Trust Advisors LP grew its stake in biote by 5.3% in the second quarter. First Trust Advisors LP now owns 73,669 shares of the company’s stock valued at $296,000 after acquiring an additional 3,675 shares during the period. Man Group plc raised its position in shares of biote by 9.9% during the third quarter. Man Group plc now owns 70,383 shares of the company’s stock worth $211,000 after purchasing an additional 6,356 shares during the period. Geode Capital Management LLC raised its position in shares of biote by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 620,256 shares of the company’s stock worth $1,613,000 after purchasing an additional 8,016 shares during the period. Renaissance Technologies LLC raised its position in shares of biote by 5.7% during the fourth quarter. Renaissance Technologies LLC now owns 203,594 shares of the company’s stock worth $529,000 after purchasing an additional 10,900 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of biote by 54.3% during the 4th quarter. Wells Fargo & Company MN now owns 32,464 shares of the company’s stock valued at $84,000 after purchasing an additional 11,427 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on BTMD. Truist Financial upgraded biote to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings raised biote from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $2.75.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.